Valuation : Exelixis, Inc.

Market Cap 1.46TCr 1.26TCr 1.18TCr 1.08TCr 2.02TCr 1,38100Cr 2.03TCr 14TCr 5.43TCr 71TCr 5.49TCr 5.37TCr 2,28200Cr P/E 2026 *
18.2x
P/E 2027 * 15.1x
Enterprise Value 1.39TCr 1.19TCr 1.12TCr 1.03TCr 1.92TCr 1,31000Cr 1.93TCr 13TCr 5.15TCr 67TCr 5.21TCr 5.1TCr 2,16600Cr EV / Sales 2026 *
5.44x
EV / Sales 2027 * 4.48x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.20%
1 week+8.37%
Current month+8.00%
1 month+4.07%
3 months+11.97%
6 months+42.95%
Current year+34.63%
1 week 53.43
Extreme 53.4283
59.72
1 month 49.97
Extreme 49.97
59.72
Current year 39.71
Extreme 39.71
59.72
1 year 33.76
Extreme 33.755
59.72
3 years 18.64
Extreme 18.64
59.72
5 years 14.87
Extreme 14.87
59.72
10 years 10.04
Extreme 10.04
59.72
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Sell

Director

-9,812 0.0039%
01/06/26 Sell

Director

-9,812 0.0039%
01/06/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+8.37%+55.78%+164.98% 1.46TCr
-1.79%-2.27%+43.23%+88.96% 6.8TCr
-2.06%-0.18%+39.67%+86.44% 6.49TCr
-0.31%+6.54%-12.96%+378.92% 2.76TCr
+0.86%+1.65%-7.74%-14.95% 2.61TCr
-3.00%-2.90%+33.13%+12.54% 2.57TCr
-1.46%+0.42%+23.61%-18.61% 2.01TCr
-2.96%-15.21%+216.20%+368.10% 1.72TCr
-1.49%-4.88%-6.60%+531.89% 1.49TCr
+2.77%+28.22%-32.24%+1,021.34% 1.4TCr
Average -0.96%+3.05%+35.21%+261.96% 2.93TCr
Weighted average by Cap. -1.31%+1.52%+34.99%+179.70%

Financials

2026 *2027 *
Net sales 255.26Cr 219.65Cr 206.66Cr 188.79Cr 353.16Cr 24TCr 354.13Cr 2.44TCr 947.64Cr 12TCr 958.54Cr 937.63Cr 40TCr 290.08Cr 249.61Cr 234.85Cr 214.53Cr 401.33Cr 27TCr 402.42Cr 2.78TCr 1.08TCr 14TCr 1.09TCr 1.07TCr 45TCr
Net income 82Cr 71Cr 66Cr 61Cr 113.54Cr 7.75TCr 113.85Cr 785.12Cr 304.66Cr 3.98TCr 308.17Cr 301.44Cr 13TCr 101.23Cr 87Cr 82Cr 75Cr 140.06Cr 9.56TCr 140.44Cr 968.5Cr 375.82Cr 4.9TCr 380.14Cr 371.85Cr 16TCr
Net Debt -74Cr -64Cr -60Cr -55Cr -103Cr -7.03TCr -103.28Cr -712.24Cr -276.38Cr -3.61TCr -279.56Cr -273.46Cr -12TCr -162.27Cr -139.63Cr -131.37Cr -120.01Cr -224.5Cr -15TCr -225.11Cr -1.55TCr -602.4Cr -7.86TCr -609.33Cr -596.04Cr -25TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
04/26/04 $59.01 -0.20% 15,80,988
03/26/03 $59.13 +1.03% 21,41,585
02/26/02 $58.53 +2.88% 28,51,454
01/26/01 $56.89 +4.12% 24,13,531
31/26/31 $54.64 +0.35% 22,46,348
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
59.01USD
Average target price
53.69USD
Spread / Average Target
-9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock